Healthcare Industry News: Mylan
News Release - September 5, 2014
Mylan Launches Generic Boniva(R) InjectionPITTSBURGH, Sept. 5, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's BonivaŽ Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of osteoporosis in postmenopausal women.
Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes had U.S. sales of approximately $18.4 million for the 12 months ending June 30, 2014, according to IMS Health.
Currently, Mylan has 288 ANDAs pending FDA approval representing $110.3 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $27.5 billion in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. Mylan.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan and Lupin Receive European Marketing Authorization for Nepexto(R), Biosimilar Etanercept
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer